Search research articles
Contact Us
Filters
Showing results (61-70 of 168) with videos related to
Page
of 17
Sort By:
The British Journal of Dermatology
|
November 3, 2018
A novel vascular tumour characterized by coexisting HRAS and GNAQ activating mutations
P Castel, S Bagué, E Granell, et al.
Critical Reviews in Oncology/Hematology
|
August 6, 2003
New drugs and new approaches in metastatic bladder cancer
J Bellmunt, R de Wit, S Albiol, et al.
Seminars in Oncology
|
October 1, 1995
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer
A D Seidman, C A Hudis, D Fennelly, et al.
Cancer
|
April 1, 1993
Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy
J Baselga, S E Krown, E E Telzak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
M Bos, J Mendelsohn, Y M Kim, et al.
Cancer Research
|
June 19, 2001
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
M A Molina, J Codony-Servat, J Albanell, et al.
Molecular Biology of the Cell
|
December 5, 2000
The carboxy-terminal cysteine of the tetraspanin L6 antigen is required for its interaction with SITAC, a novel PDZ protein
M Borrell-Pagès, J Fernández-Larrea, A Borroto, et al.
Oncology (Williston Park, N.Y.)
|
March 1, 1997
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience
A D Seidman, C A Hudis, G Raptis, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1991
A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma
E S Casper, J Baselga, T B Smart, et al.
Journal of the National Cancer Institute
|
August 18, 1993
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
J Baselga, L Norton, H Masui, et al.
Page
of 17
Search research articles
Search
Showing results (61-70 of 168) with videos related to
Sort By:
Page
of 17
The British Journal of Dermatology
|
November 3, 2018
A novel vascular tumour characterized by coexisting HRAS and GNAQ activating mutations
P Castel, S Bagué, E Granell, et al.
Critical Reviews in Oncology/Hematology
|
August 6, 2003
New drugs and new approaches in metastatic bladder cancer
J Bellmunt, R de Wit, S Albiol, et al.
Seminars in Oncology
|
October 1, 1995
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer
A D Seidman, C A Hudis, D Fennelly, et al.
Cancer
|
April 1, 1993
Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy
J Baselga, S E Krown, E E Telzak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
M Bos, J Mendelsohn, Y M Kim, et al.
Cancer Research
|
June 19, 2001
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
M A Molina, J Codony-Servat, J Albanell, et al.
Molecular Biology of the Cell
|
December 5, 2000
The carboxy-terminal cysteine of the tetraspanin L6 antigen is required for its interaction with SITAC, a novel PDZ protein
M Borrell-Pagès, J Fernández-Larrea, A Borroto, et al.
Oncology (Williston Park, N.Y.)
|
March 1, 1997
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience
A D Seidman, C A Hudis, G Raptis, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1991
A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma
E S Casper, J Baselga, T B Smart, et al.
Journal of the National Cancer Institute
|
August 18, 1993
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
J Baselga, L Norton, H Masui, et al.
Page
of 17